{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:33:46Z","timestamp":1792870426460,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jacc.2021.01.033","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T07:40:11Z","timestamp":1616053211000},"page":"1381-1392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"title":["Empagliflozin in Patients With Heart\u00a0Failure, Reduced Ejection Fraction, and Volume Overload"],"prefix":"10.1016","volume":"77","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waheed","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.01.033_bib1","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.01.033_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.01.033_bib3","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","author":"Boorsma","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.01.033_bib4","first-page":"779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors","volume":"8","author":"Eickhoff","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacc.2021.01.033_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2021.01.033_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.01.033_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.01.033_bib8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.01.033_bib9","article-title":"Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.01.033_bib10","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.clinthera.2016.08.008","article-title":"Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus","volume":"38","author":"Heise","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacc.2021.01.033_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.109.933275","article-title":"Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival","volume":"122","author":"Testani","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.01.033_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cardfail.2018.09.014","article-title":"Biochemical determinants of changes in plasma volume after decongestion therapy for worsening heart failure","volume":"25","author":"Kataoka","year":"2019","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2021.01.033_bib13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/nep.13552","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: a comparison study with furosemide and tolvaptan","volume":"24","author":"Ohara","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.jacc.2021.01.033_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","article-title":"Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress","volume":"117","author":"Packer","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2021.01.033_bib15","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.jacc.2020.09.004","article-title":"Effects of canagliflozin on amino-terminal pro-B-type natriuretic peptide: implications for cardiovascular risk reduction","volume":"76","author":"Januzzi","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.01.033_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2021.01.033_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1479164115616901","article-title":"Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus","volume":"13","author":"Neeland","year":"2016","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jacc.2021.01.033_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13098-020-00545-z","article-title":"The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease","volume":"12","author":"Ohara","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jacc.2021.01.033_bib19","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1007\/s00380-020-01597-x","article-title":"Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients with coexisting type 2 diabetes mellitus","volume":"35","author":"Fukuoka","year":"2020","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacc.2021.01.033_bib20","first-page":"2932","article-title":"Six-month predictive value of diuretic resistance formulas in discharged heart failure patients after an acute decompensation","volume":"9","author":"Feola","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacc.2021.01.033_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240098","article-title":"The development of chronic diuretic resistance can be predicted during a heart-failure hospitalization. Results from the REDIHF registry","volume":"15","author":"Bl\u00e1zquez-Bermejo","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2021.01.033_bib22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11739-018-02019-7","article-title":"Prevalence and outcome of diuretic resistance in heart failure","volume":"14","author":"Trull\u00e0s","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jacc.2021.01.033_bib23","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ehf2.12759","article-title":"Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series","volume":"7","author":"Griffin","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2021.01.033_bib24","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.01.033_bib25","doi-asserted-by":"crossref","first-page":"e003180","DOI":"10.1161\/CIRCHEARTFAILURE.116.003180","article-title":"Hypochloremia and diuretic resistance in heart failure: mechanistic insights","volume":"9","author":"Hanberg","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.01.033_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","article-title":"Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial","volume":"44","author":"Scholtes","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2021.01.033_bib27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2021.01.033_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.01.033_bib29","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.01.033_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial","volume":"228","author":"Jensen","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2021.01.033_bib31","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jdiacomp.2019.05.001","article-title":"Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors","volume":"33","author":"Weeda","year":"2019","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.jacc.2021.01.033_bib32","doi-asserted-by":"crossref","first-page":"107729","DOI":"10.1016\/j.jdiacomp.2020.107729","article-title":"Correction of anemia by dapagliflozin in patients with type 2 diabetes","volume":"34","author":"Stef\u00e1nsson","year":"2020","journal-title":"J\u00a0Diabetes Complications"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2021.01.033_bib33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/ndt\/5.suppl_1.102","article-title":"The haemodynamic effects of correction of anaemia in haemodialysis patients using recombinant human erythropoietin","volume":"5","author":"Abdulhadi","year":"1990","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2021.01.033_bib34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.01.033_bib35","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2021.01.033_bib36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000507272","article-title":"Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes","volume":"51","author":"Marathias","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2021.01.033_bib37","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.01.033_bib38","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.119.045561","article-title":"Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance","volume":"141","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.01.033_bib39","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ejhf.1732","article-title":"Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.01.033_bib40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2020","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721002023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721002023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:38:44Z","timestamp":1760017124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721002023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0735109721002023"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.01.033","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin in Patients With Heart\u00a0Failure, Reduced Ejection Fraction, and Volume Overload","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}